Delivery Order SPE2DE21D0005-SPE2D625F9Y4D
- Not listed
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $3,400 on July 17, 2025, by the Defense Logistics Agency's Medical Supply Chain division. The delivery order, which carries a fixed-price contract type with economic price adjustment provisions, is for PURAPLY AM XT EF, a 5-layer fenestrated advanced wound care product. The contract does not utilize a set-aside designation, indicating Organogenesis competed as a standard...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a $3,400 fixed-price delivery order with economic price adjustment authority by the Defense Logistics Agency's Medical Supply Chain on October 1, 2025. The delivery order is for PURAPLY AM XT EF, a five-layer fenestrated advanced wound care product, with an ultimate completion date of October 6, 2025. This award was made without any set-aside designation, indicating that Organogenesis competed as a...
- Organogenesis Inc. was awarded a $8,500 delivery order by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, for PURAPLY AM XT EF, a five-layer fenestrated advanced wound care product. The contract is structured as a fixed-price agreement with economic price adjustment provisions and is scheduled for completion by July 28, 2025. The work will be performed at Organogenesis' headquarters in Canton, Massachusetts. No set-aside designation was utilized for this award, indicating...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $5,790.00 by the Defense Logistics Agency's Medical Supply Chain on August 11, 2025, with an ultimate completion date of August 14, 2025. The contract is for PURAPLY AM XT 4.91X4.91, an advanced wound care dressing used for surgical and wound treatment applications. The award utilized fixed-price pricing with economic price adjustment provisions and was not designated as a...
- Organogenesis Inc., a Canton, Massachusetts-based regenerative medicine company, was awarded a delivery order valued at $1,504.00 by the Defense Logistics Agency's Medical Supply Chain division on September 25, 2025. The contract, classified as a fixed-price award with economic price adjustment provisions, calls for the delivery of PURAPLY Micronized 500mg and is scheduled for completion by September 30, 2025. No small business or other set-aside designation was utilized in this competitive...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, has been awarded a delivery order by the Defense Logistics Agency (DLA) Medical Supply Chain for PURAPLY AM XT 4.91X4.91 wound care dressings. The fixed-price delivery order, valued at $11,580.00, was awarded on August 15, 2025, with an ultimate completion date of August 20, 2025. The contract carries no set-aside designation, allowing the company to compete as a standard commercial vendor. The place of...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $2,479.90 by the Defense Logistics Agency's Medical Supply Chain division on September 23, 2025. The contract, which operates under a fixed-price arrangement with economic price adjustment provisions, is for the supply of APLIGRAF, an advanced wound care and tissue regeneration product. The delivery order is scheduled for completion by September 26, 2025, and was awarded...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a $17.82K delivery order on September 9, 2025, for PURAPLY SX 6CM x 9CM wound care dressings. This fixed-price contract with economic price adjustment carries an ultimate completion date of September 12, 2025, and is being funded through the Medical Supply Chain, a defense-oriented federal agency. The award was made on a competitive basis with no set-aside designation, reflecting...
- Organogenesis Inc., a Canton, Massachusetts-based regenerative medicine company, received a delivery order award valued at $1,239.95 from the Defense Logistics Agency's Medical Supply Chain for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 7, 2025, carries a fixed price structure with economic price adjustment provisions and is scheduled for completion by May 12, 2025. No set-aside designation was used in this award, indicating Organogenesis...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,118.88 fixed-price delivery order with economic price adjustment to Organogenesis Inc., a leading regenerative medicine company based in Canton, Massachusetts. The order is for PURAPLY AM (2x2) 4 SQ CM, an advanced wound care product. This order is part of Organogenesis' broader federal contract vehicles, including a $49.5 million multiple-award Indefinite Delivery Contract with DLA Troop Support Medical for wound care...
- SPE2DE21D0005Indefinite Delivery Contract
- SPE2DE21D0005-SPE2D625F9Y4DDelivery Order
Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a $8,500 fixed-price delivery order with economic price adjustment by the Defense Logistics Agency's Medical Supply Chain division on May 30, 2025. The delivery order, with an ultimate completion date of June 4, 2025, covers PURAPLY AM XT EF, a five-layer fenestrated advanced wound care product. This award was made without a set-aside designation, indicating that Organogenesis competed as a standard commercial vendor. The place of performance is Canton, Massachusetts, where Organogenesis manufactures its regenerative medicine and wound care products. This delivery order is issued under one of Organogenesis's larger indefinite delivery contract vehicles with the Defense Logistics Agency Troop Support Medical, a $49.5 million multiple-award contract running through June 2026 that was established as a total small business set-aside. PURAPLY AM XT is part of Organogenesis's comprehensive portfolio of wound care and surgical biologics supplied to military and veteran healthcare systems. The company's established federal contracting relationships with the Defense Logistics Agency and Department of Veterans Affairs position it as a key supplier of advanced wound treatment solutions for government healthcare programs supporting military personnel and veterans.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 5/30/25 |